Literature DB >> 16619274

PET-CT vs contrast-enhanced CT: what is the role for each after chemoradiation for advanced oropharyngeal cancer?

Amy Y Chen1, Isabel Vilaseca, Patricia A Hudgins, David Schuster, Ragheev Halkar.   

Abstract

PURPOSE: The aim of our study was to assess the utility of positron emission tomography (PET) and 2 fluoro-2-deoxy-D-glucose coupled with neck CT compared with contrast-enhanced CT in predicting persistent cancer either at the primary site or cervical lymphatics in patients with oropharyngeal cancer treated with concurrent chemoradiation
METHODS: Thirty consecutive patients underwent clinical examination, PET-CT, and contrast-enhanced CT to assess response after the completion of the treatment. The outcome variable was positive tissue diagnosis or negative disease at 6 months. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated for the primary site as well as cervical disease.
RESULTS: Contrast-enhanced CT alone showed the best accuracy in detecting disease at the primary site after treatment (85.7%). Accuracy in evaluating residual tumor in the cervical lymphatics for contrast-enhanced CT and PET-CT was 59.3% and 74.1%, respectively. For evaluating the neck, PET-CT and contrast-enhanced CT demonstrated 100% NPV, but the PPV was 36.3% and 26.6%, respectively.
CONCLUSIONS: In this preliminary study, PET-CT seems to be superior to contrast-enhanced CT in predicting persistent disease in the neck after chemoradiation for oropharyngeal or unknown primary cancer, but not at the primary site. However, the possibility of a false-positive result in the neck remains high, and thus overtreatment may result. Even more concerning are the false-negative results. Larger, prospective studies will be important in defining the role of PET-CT in obviating the need for salvage neck dissections after chemoradiation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16619274     DOI: 10.1002/hed.20362

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  15 in total

Review 1.  The role of FDG PET-CT in the therapeutic evaluation for HNSCC patients.

Authors:  Joji Kawabe; Shigeaki Higashiyama; Atsushi Yoshida; Kohei Kotani; Susumu Shiomi
Journal:  Jpn J Radiol       Date:  2012-04-05       Impact factor: 2.374

2.  Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis.

Authors:  Tejpal Gupta; Zubin Master; Sadhana Kannan; Jai Prakash Agarwal; Sarbani Ghsoh-Laskar; Venkatesh Rangarajan; Vedang Murthy; Ashwini Budrukkar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-19       Impact factor: 9.236

Review 3.  Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.

Authors:  Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra
Journal:  Br J Radiol       Date:  2016-08-02       Impact factor: 3.039

4.  Post-treatment 18F-FDG-PET/CT versus contrast-enhanced CT in patients with oropharyngeal squamous cell carcinoma: comparative effectiveness study.

Authors:  Mehdi Taghipour; Esther Mena; Matthew J Kruse; Sara Sheikhbahaei; Rathan M Subramaniam
Journal:  Nucl Med Commun       Date:  2017-03       Impact factor: 1.690

5.  Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.

Authors:  Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

6.  Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma.

Authors:  Jason Y K Chan; Giuseppe Sanguineti; Jeremy D Richmon; Shanthi Marur; Christine G Gourin; Wayne Koch; Christine H Chung; Harry Quon; Justin A Bishop; Nafi Aygun; Nishant Agrawal
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2012-11

7.  The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings.

Authors:  Munetaka Matoba; Hiroyuki Tuji; Yuzo Shimode; Tamaki Kondo; Kiyotaka Oota; Hisao Tonami
Journal:  Br J Radiol       Date:  2017-01-05       Impact factor: 3.039

8.  PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma.

Authors:  Shu-Hang Ng; Sheng-Chieh Chan; Tzu-Chen Yen; Chun-Ta Liao; Chin-Yu Lin; Joseph Tung-Chieh Chang; Sheung-Fat Ko; Hung-Ming Wang; Kai-Ping Chang; Kang-Hsing Fan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-15       Impact factor: 9.236

9.  Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck.

Authors:  Lale Kostakoglu; Reza Fardanesh; Marshall Posner; Peter Som; Srikar Rao; Eunice Park; John Doucette; Evan G Stein; Vishal Gupta; Krzysztof Misiukiewicz; Eric Genden
Journal:  Oncologist       Date:  2013-09-13

10.  Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer.

Authors:  Benjamin J Moeller; Vishal Rana; Blake A Cannon; Michelle D Williams; Erich M Sturgis; Lawrence E Ginsberg; Homer A Macapinlac; J Jack Lee; K Kian Ang; K S Clifford Chao; Gregory M Chronowski; Steven J Frank; William H Morrison; David I Rosenthal; Randal S Weber; Adam S Garden; Scott M Lippman; David L Schwartz
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.